<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03808090</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-130502007</org_study_id>
    <secondary_id>1K08DK115833-01A1</secondary_id>
    <nct_id>NCT03808090</nct_id>
  </id_info>
  <brief_title>Obesity and Endogenous Oxalate Synthesis</brief_title>
  <official_title>Obesity and Endogenous Oxalate Synthesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this proposal is to determine the contribution and significance of obesity to
      urinary oxalate excretion and thus calcium oxalate kidney stone disease. Successful
      completion of the study will provide insight into the link between obesity and kidney stone
      disease and should identify future strategies to treat this disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2013</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary oxalate excretion</measure>
    <time_frame>Baseline through 2 months</time_frame>
    <description>Urinary oxalate excretion from 24 hour urine collections will be reported as mg/day</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Obesity</condition>
  <condition>Kidney Stone</condition>
  <arm_group>
    <arm_group_label>Normal Individuals</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal individuals: no prior history of KS, no obesity, no diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium Oxalate Kidney Stone Formers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Those individuals that have a high propensity to form calcium oxalate kidney stones</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 2 Diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Those individuals that have been diagnosed with type 2 diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 2 diabetic kidney stone formers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Those individuals that have been diagnosed with type 2 diabetes and kidney stones.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Individuals</intervention_name>
    <description>Stage I: Controlled Dietary Study Phase II: Glycolate Phase III: Vitamin C Participants that agree,will undergo MRI to evaluate fatty liver</description>
    <arm_group_label>Normal Individuals</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Calcium Oxalate Kidney Stone Formers</intervention_name>
    <description>Stage I: Controlled Dietary Study Phase II: Glycolate Phase III: Vitamin C Participants that agree,will undergo MRI to evaluate fatty liver</description>
    <arm_group_label>Calcium Oxalate Kidney Stone Formers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Type 2 Diabetes</intervention_name>
    <description>Stage I: Controlled Dietary Study Phase II: Glycolate Phase III: Vitamin C Participants that agree,will undergo MRI to evaluate fatty liver</description>
    <arm_group_label>Type 2 Diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Type 2 diabetic kidney stone formers</intervention_name>
    <description>Stage I: Controlled Dietary Study Phase II: Glycolate Phase III: Vitamin C Participants that agree,will undergo MRI to evaluate fatty liver</description>
    <arm_group_label>Type 2 diabetic kidney stone formers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index (BMI) &lt; 30

          -  Calcium oxalate stone formers with passage or removal of a kidney stone containing &gt;
             50% calcium oxalate

          -  Type 2 Diabetics with fasting glucose &gt; 126 mg/dL or hemoglobin A1c greater than or
             equal to 6.5%

        Exclusion Criteria:

          -  Any disease that will affect the urinary excretion of oxalate, calcium or another ion
             that will compromise the interpretation of results.

          -  Abnormal urine chemistries or blood metabolic profiles

          -  A glomerular filtration rate (GFR) or estimated GFR &lt; 60 mls/min

          -  Pregnancy

          -  Body Mass Index (BMI) &gt; 32
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyle D Wood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Demond Wiley</last_name>
    <phone>205-934-3671</phone>
    <email>kidneystone@uabmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Billy Tingle, RN</last_name>
      <phone>205-934-3671</phone>
      <email>billy@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Kyle D Wood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>December 26, 2018</study_first_submitted>
  <study_first_submitted_qc>January 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2019</study_first_posted>
  <last_update_submitted>August 8, 2019</last_update_submitted>
  <last_update_submitted_qc>August 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Kyle D. Wood</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>oxalate</keyword>
  <keyword>obesity</keyword>
  <keyword>kidney stones</keyword>
  <keyword>diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

